Pharming Group N.V. (PHAR) Q4 2023 Earnings
PHAR·Reported May 8, 2024·Before market open
Pharming Group N.V. reported Q4 2023 revenue of $90.0M, beat analyst consensus of $68.4M by $21.6M. Diluted EPS came in at $-0.19, missed the $0.01 consensus by $0.20.
Revenue
$90.0Mbeat by $21.6M
Consensus: $68.4MDiluted EPS
$-0.19missed by $0.20
Consensus: $0.01
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q4 2023 Earnings FAQ
Common questions about Pharming Group N.V.'s Q4 2023 earnings report.
Pharming Group N.V. (PHAR) reported Q4 2023 earnings on May 8, 2024 before market open.
Pharming Group N.V. reported revenue of $90.0M and diluted EPS of $-0.19 for Q4 2023.
Revenue beat the consensus estimate of $68.4M by $21.6M. EPS missed the consensus estimate of $0.01 by $0.20.